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Aims: Up-regulation of the endothelin (ET) system in type-2 diabetes increases contraction and decreases
relaxation in basilar artery. We showed that 1) ET-receptor antagonism prevents diabetes-mediated cerebro-
vascular dysfunction; and 2) glycemic control prevents activation of the ET-system in diabetes. Here, our goal
is to determine whether and to what extent glycemic control or ET-receptor antagonism reverses established
cerebrovascular dysfunction in diabetes.
Main methods: Non-obese type-2 diabetic Goto–Kakizaki rats were administered either vehicle, metformin
(300 mg/kg/day) or dual ET-receptor antagonist bosentan (100 mg/kg) for 4-weeks starting at 18-weeks after
established cerebrovascular dysfunction (n = 5–6/group). Control group included vehicle-treated aged-
matched Wistar rats. Blood glucose and pressure were monitored weekly. At termination, basilar arteries were
collected and cumulative dose–response curves to ET-1 (0.1–500 nM), 5-HT (1–1000 nM) and acetylcholine
(Ach, 0.1 nM–5 μM) were studied by wire myograph. Middle cerebral artery (MCA) myogenic reactivity and
tone were measured using pressurized arteriograph.
Key ﬁndings: There was no difference in ET-1 and 5-HT-mediated constrictions. Endothelium-dependent
relaxation was impaired in diabetes. Bosentan improved sensitivity to Ach as well as the maximum relaxation.
Myogenic-tone is decreased over the course of the disease. Both treatments improved the ability of MCAs to
develop tone at 80 mm Hg and only bosentan improved the tone at higher pressures.
Signiﬁcance: These results suggest that contractile response is not affected by glycemic control or ET-receptor
antagonism. Meanwhile, dual ET-receptor blockade is effective in partially improving endothelium-dependent
relaxation and myogenic response in a blood pressure-independent manner even after established cerebro-
vascular dysfunction and offers therapeutic potential.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Diabetes increases the risk and severity of cerebrovascular diseases
such as ischemic stroke and vascular cognitive impairment (Kodl and
Seaquist, 2008; Ergul et al., 2012). Diabetes is also associated with
decreased cerebral blood ﬂow, which is increasingly recognized as a
major factor contributing to the development and progression of cogni-
tive deﬁcits in this population (Kodl and Seaquist, 2008). Undoubtedly,
regulation of cerebrovascular tone is important for maintenance
of proper blood ﬂow (Faraci and Heistad, 1990). Myogenic and agonist-
induced reactivity of the cerebral vasculature play a key role in
controlling cerebral blood ﬂow, and large arteries like basilar arteryy, Georgia Regents University,
USA. Tel.: +1 706 721 9103;
. This is an open access article undercontribute signiﬁcantly to regulation of cerebrovascular resistance
(Faraci and Heistad, 1990). Thus, vascular dysfunction could contribute
to cerebrovascular disease, and indeed, a number of studies have
shown that diabetes alters myogenic tone and impairs endothelium-
derived relaxation in experimental models (Dumont et al., 2003; Harris
et al., 2008; Kelly-Cobbs et al., 2012). We have shown that myogenic
tone is increased early in disease but as cerebral blood vessels remodel,
they lose their ability to develop tone, and glycemic control started at
the onset of diabetes prevents this change in myogenic tone (A. Kelly-
Cobbs et al., 2011; A.I. Kelly-Cobbs et al., 2011). Whether and to what
extent diabetes-mediated cerebrovascular dysfunction can be reversed
if glycemic control is initiated later in the disease is not known.
It is well established that the potent vasoconstrictor endothelin-1
(ET-1) and cognate receptors, ETA and ETB (Goto et al., 1996), are
activated in both clinical and experimental diabetes (Takahashi et al.,
1990; Collier et al., 1992). ETA receptors residing on the smooth muscle
cell (SMC) produce vasoconstriction and mediate the proliferative
effects of ET-1,while endothelial ETB counteracts these effects. However,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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tors in the cerebrovasculature in diabetes (A. Kelly-Cobbs et al., 2011;
A.I. Kelly-Cobbs et al., 2011); and 2) selective ETA, selective ETB or dual
ET receptor blockade is vasculoprotective and prevents diabetes-
mediated cerebrovascular dysfunction (Harris et al., 2005; A. Kelly-
Cobbs et al., 2011; A.I. Kelly-Cobbs et al., 2011). We further demons-
trated that glycemic control prevents activation of the ET system in
diabetes (Sachidanandam et al., 2009), which is associated with
improved vascular function (A. Kelly-Cobbs et al., 2011; A.I. Kelly-
Cobbs et al., 2011). While these studies provided important evidence
with regard to preventive cerebrovascular protective role of ET-1 an-
tagonism, the therapeutic efﬁcacy remained unknown. In this study,
we tested the hypothesis that dual ET-1 receptor antagonism reverses
established myogenic and endothelial dysfunction in diabetes.
Materials and methods
Animals
All experiments were performed using male Wistar rats (Harlan;
Indianapolis, ID) and age-matched diabetic GK rats (In-house bred, de-
rived from the Tampa colony or purchased from the Tampa colony,
Taconic; Hudson, NY). We have chosen this non-obese model of type
2 diabetes because diabetes-induced cerebrovascular alterations can
be studied in the absence of confounding comorbidities such as hyper-
tension or hyperlipidemia. The animals were housed at the Georgia Re-
gents University animal care facility that is approved by the American
Association for Accreditation of Laboratory Animal Care. All protocols
were approved by the institutional animal care and use committee.
Animals were fed standard rat chow and tap water ad libitum.
Starting at 18 weeks of age after the development of diabetes-
induced cerebrovascular dysfunction, the following groups (n = 5–6/
group) were treated for 4 weeks: 1) GK vehicle, 2) GK + metformin
(300 mg/kg/day in drinking water which we showed to achieve effec-
tive glycemic control in previous studies (Sachidanandam et al., 2009;
Elgebaly et al., 2010)), 3) GK + bosentan (100 mg/kg/day by oral
gavage), and 4) control Wistar vehicle. In additional groups (n = 5/
group) of 10 and 18 week-old diabetic GK rats, myogenic reactivity
was measured to investigate the impact of disease duration on tone
development. Body weights and blood glucose measurements were
taken biweekly. Blood glucose measurements were taken from tail
vein samples using a commercially available glucometer (Freestyle,
Abbott Diabetes Care, Inc.; Alameda, CA). Mean arterial pressure
(MAP, mm Hg) was measured using the tail-cuff method. All animals
were anesthetized with pentobarbital sodium (Fatal-Plus, Vortech
Pharmaceuticals Ltd.; Dearborn, MI), exsanguinated via cardiac punc-
ture, and decapitated to extract the brain. Middle cerebral arteries
(MCA) and basilar arteries (BA) were isolated for functional studies
with pressurized arteriograph and myograph, respectively.
Myogenic function studies
MCAs were quickly excised and used within 45 min of isolation to
ensure viability of the vessels. A pressure arteriograph system (Living
Systems; Burlington, VT)was used to evaluateMCAmyogenic reactivity
and tone. For these studies, MCA segments approximately 200–250 μm
in diameter and proximal to the junction between the MCA and the
inferior cerebral vein were used exclusively. Vessels were ﬁrstmounted
onto glass cannulas in an arteriograph chamber and HEPES bicarbonate
buffer (in mM: 130 NaCl, 4 KCl, 1.2 MgSO4, 4 NaHCO3, 10 HEPES, 1.18
KH2PO4, 5.5 glucose, 1.8 CaCl2) was circulated and maintained at
37 ± 0.5 °C. MCA segments were then pressurized at 60 mm Hg for
1 h to generate spontaneous tone. A video dimension analyzer connect-
ed to the arteriograph systemwas used tomeasuremedia thickness (MT)
and lumen diameter (LD) at pressures ranging from 5 to 180 mm-Hg, in
20 mm-Hg increments. The ﬁrst measurement was taken at 5 mm Hgbecause negative pressure is generated at 0 mm Hg, causing the vessel
to collapse. All vessels were exposed to each pressure point for 5 min
before readings were recorded. Pressure-diameter curves were obtained,
ﬁrst in the presence of Ca2+ to observe the vessels' contractile properties,
and then in Ca2+-free buffer with the addition of 10−7 M papaverine
hydrochloride to evaluate the vessels' passive properties. Using the
outer diameter (OD) measurements obtained in active conditions (in
the presence of Ca2+) and in passive conditions (in the absence of
Ca2+), Percent Myogenic Tone (% tone) = 1 − (Active OD / Passive
OD) × 100 was calculated over the entire pressure range (20–180 mm-
Hg) and tones at 80 and 120 mm-Hg were reported to represent mid
and high end of the pressure curve, respectively.
Endothelial function studies
Isometric tension exerted byBAswas recorded via a force transducer
using the wire-myograph technique (Danish Myo Technologies,
Denmark). The myograph chambers were ﬁlled with Krebs buffer
(NaCl 118.3, NaHCO3 25, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.5 and
Dextrose 11.1 mM), gassed with 95% O2 and 5% CO2 and maintained
at 37 °C. Vessel segments were mounted in the chamber using 40 μm-
thin wires and adjusted to a baseline tension of 0.4 g. Buffer was then
switched to 70 mM KCl containing Krebs buffer in which NaCl concen-
trationwas reduced to achieve similar osmolarity and endothelial integ-
rity was checked by relaxation response to 1 μM acetylcholine (Ach).
Chambers were washed, reﬁlled with regular Krebs buffer and cumula-
tive dose–response curves to serotonin 5-HT (1–1000 nM) and ET-1
(0.1–500 nM) were generated. The force generated was expressed as
% change of KCl. Endothelium-dependent relaxation to Ach (1 nM–
1 μM) was assessed directly after ET-1 dose–response. Sensitivity
(EC50) and maximum response (Rmax) values were calculated from
the respective dose–response equations.
Statistical analysis
Results are given asmean ± SEM. For EC50 and Rmax values, analysis
of variance (ANOVA) was performed with a post-hoc Tukey test. A
repeated measures ANOVA was used to determine group differences
(Diabetic vs. Control) across the ET-1 or Ach concentrations. Post-hoc
group comparisons at each concentration used a Tukey's adjustment
for the multiple comparisons. Graphpad Prism 5.0 was used for all
statistical tests performed.
Results
Effect of bosentan and metformin on metabolic proﬁle
Bodyweight was slightly lower and blood glucose higher in diabetic
animals as compared to control. Treatment with metformin did not
affect body weight or blood pressure but bosentan increased blood
pressure in diabetic animals (Table 1).
Effect of bosentan and metformin on contractile response
ET-1mediated constriction is a dose dependentmanner (Fig. 1A) but
there was no difference among the groups with respect to maximal
contraction or sensitivity to ET-1 (Fig. 1B and C). KCl and HT-induced
contractions were also similar in all groups (data not shown).
Effect of bosentan and metformin on relaxation response
Endothelium-dependent relaxation to Ach was signiﬁcantly im-
paired; i.e. maximum relaxation was less and EC50 was higher indicating
reduced sensitivity, in diabetic animals as compared to age-matched con-
trol animals (Fig. 2A). While it did not reach statistical signiﬁcance, only
bosentan increased relaxation (Rmax) despite elevated blood pressure
Table 1
Animal characteristics (*P b 0.05).
Control Diabetes Diabetes + metformin Diabetes + bosentan
Body weight
(g)
443 ± 14 371 ± 5* 371 ± 6* 377 ± 12*
Blood glucose
(mg/dl)
112 ± 9 228 ± 26* 126 ± 5 199 ± 20*
Mean arterial pressure
(mm-Hg)
97.6 ± 4 108 ± 5 105 ± 5 120 ± 5*
265M. Abdelsaid et al. / Life Sciences 118 (2014) 263–267(Fig. 2B). The response curve in themetformin groupwas almost ﬂat and
therefore nonlinear regression analysis is not dependable to report an
EC50 value. Bosentan, however, improved sensitivity to Ach (Fig. 2C).
Effect of treatment and duration of disease on myogenic response
Myogenic tone was lower in diabetic rats as compared to age-
matched control group (Fig. 3A). Treatment with metformin and
bosentan restored tone at 80 mm-Hg pressure but only bosentan was
effective in improving tone at higher pressure (Fig. 3A). Diabetic
animals developed higher pressure shortly after onset of diabetes atA
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Fig. 1. Effect of glycemic control and endothelin receptor antagonism on ET-1-induced
isometric contractions in basilar arteries in diabetes. (A) Dose–response curves to ET-1
in control (C), diabetes (D), diabetes + bosentan (D + B) and diabetes + metformin
(D + M) groups were similar. There was no difference in maximum response (B) or
sensitivity (C) to ET-1 among the groups. Contractile response was expressed as % KCl
response and results are given as mean ± SEM, n = 5–6/group.10 weeks of age but by 18 weeks myogenic tone decreased and
remained lower till 22 weeks (Fig. 3B).Discussion
We have shown that dual ET receptor antagonism is an effective
preventive vasculoprotection strategy in decreasing hypersensitivity
to ET-1 and improving vascular relaxation of basilar arteries in diabetes
when treatment is started at the onset of diabetes. The current study
was designed to test the hypothesis that dual ET-1 receptor antagonism
will be as effective in reversing established myogenic and endothelial
dysfunction in diabetes. Our results demonstrate that 1) bosentan treat-
ment is as effective, if not better, as glycemic control with metformin inA
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Fig. 2. Effect of glycemic control and endothelin receptor antagonism on endothelium-
dependent vasorelaxation in basilar arteries in diabetes. (A) Dose–response curves to
Ach in ET-1-preconstricted vessels showed severely impaired vasorelaxation in diabetic
animals. (B) Maximum relaxation to Ach (Rmax) was signiﬁcantly lower in diabetic
animals. While metformin had no effect on Rmax, bosentan improved it. (C) Sensitivity
to Ach was decreased in diabetes as indicated by greater EC50 values. Bosentan improved
sensitivity. Since the metformin dose–response curve was ﬂat, EC50 was not determined
(ND) for this group. Results are given as mean ± SEM, n = 5–6/group. #p b 0.001,
*p b 0.05 vs. C, **p b 0.05 vs. D + M.
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Fig. 3. Effect of glycemic control and endothelin receptor antagonism onpressure-induced
myogenic tone of isolated MCAs. (A) Myogenic tone at 80 and 120 mm-Hg was lower in
diabetic animals and bosentan improved tone development. (B) MCA myogenic tone
was decreased during the disease progression in diabetes and only bosentan improved
tone at higher pressure points. Mean ± SEM, n = 5–6, *p b 0.05 vs. control, **p b 0.05
vs. D, #p b 0.05 vs. 10 w, ##p b 0.05 vs. 22w D.
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of larger cerebral arteries, 2) this protective effect is independent of
changes in blood pressure, and 3) the gradual decline in myogenic
tone of middle cerebral arteries in early diabetes does not further
progress in the disease process.
Accumulating evidence suggests that cerebrovascular disease and
alterations in cerebral blood ﬂow (CBF) are important for stroke and
neurodegenerative diseases such as dementia and Alzheimer's disease
in patients with diabetes (Kodl and Seaquist, 2008; Ergul et al., 2012).
CBF is tightly regulated to meet the constant energy demands and
proper function of the brain (Iadecola and Nedergaard, 2007). Cerebro-
vascular autoregulation is essential for maintaining constant CBF de-
spite changes in cerebral perfusion pressure and this is achieved by
the regulation of vascular tone by myogenic, neuronal, and ligand-
dependent mechanisms (Faraci and Heistad, 1998). Large arteries like
BAs and MCAs contribute signiﬁcantly to cerebrovascular resistance
(Faraci and Heistad, 1990; Palomares and Cipolla, 2011). Thus, a num-
ber of studies including our own investigated the impact of diabetes
on vascular function in these vascular beds and reported enhanced con-
striction, reduced vasodilatation and/or impaired myogenic reactivity
leading to increased tone and reduced CBF (Zimmermann et al., 1997;
Jarajapu et al., 2008; Ergul et al., 2012; Kelly-Cobbs et al., 2012). We
have shown that myogenic tone is increased and is associated with re-
duced CBF in early diabetes (10 weeks) as compared to nondiabetic
counterparts but as disease progresses MCAs remodel and develop
less tone by 18 weeks of age (A. Kelly-Cobbs et al., 2011; A.I. Kelly-
Cobbs et al., 2011; Kelly-Cobbs et al., 2012). Glycemic control with met-
formin prevented this decrease in MCA tone when the treatment was
started at the onset of diabetes. In the current study, we used both
BAs and MCAs to assess agonist-induced (contractile and dilatory func-
tion) and pressure-induced (myogenic function) vasoreactivity. Thecurrent study further expanded our previous observations and showed
that decreased tone persists up to 22 weeks and it can be partially re-
stored to control levels even if blood glucose is regulated after the
onset of myogenic dysfunction.
Endothelial dysfunction is a prominent feature of cardiovascular
diseases and also plays an important role in both micro and macro-
vascular complications of diabetes (Jansson, 2007; Versari et al., 2009).
In early stages, the imbalance of increased vasoconstrictors like ET-1
and decreased bioavailability of vasodilator nitric oxide (NO) due to
hyperglycemia-driven oxidative stress results in impaired vasorelax-
ation (Kalani, 2008). As the disease progresses, the prolonged loss of
protective effects ofNO and the activation of the ET system lead to struc-
tural alterations, thrombosis and plaque development in the vessel wall
(Kalani, 2008; Ergul, 2011). Increasing evidence suggests that ET-1 is
involved in the pathology of cerebrovascular disease (Khan and
Chakrabarti, 2003; Ergul, 2011). Contractile responses to ET-1 are
augmented in the rat and rabbit basilar arteries of type 1 diabetic rats,
respectively (Alabadi et al., 2004; Matsumoto et al., 2004), and
augmented myogenic tone is decreased after ET receptor antagonism
in type 1 diabetes (Dumont et al., 2003). We have shown that early in
the disease basilar arteries from diabetic GK rats exhibit increased sen-
sitivity to ET-1 (Harris et al., 2008). Endothelium-dependent relaxation
was also impaired in this study. In the current study, we used older
animals and did not observe a difference in the contractile response to
ET-1 between control and diabetic animals; however, endothelial
dysfunction remained to be a prominent feature of cerebrovascular
dysfunction observed in this model and even further suppressed.
Given the potential involvement of ET-1 in cerebral complications of
diabetes, in a series of studies we investigated the relative role(s) of ET
receptors in diabetic cerebrovascular dysfunction. While selective ETA
receptor blockade restored relaxation to control values in the GK
animals and selective ETB blockade caused paradoxical constriction in
diabetes (Harris et al., 2008) suggesting that there may be an upregula-
tion of vascular smooth muscle ETB receptors in diabetes. We next
showed that dual antagonism to be as effective as selective ETA blockade
in prevention of basilar artery dysfunction in diabetes and suggested
that when blocked simultaneously with the ETA receptor, the ETB recep-
tor antagonism is protective by improving cerebrovascular endothelial
dysfunction in diabetes (Li et al., 2011). Building on this foundation,
the current study evaluated the efﬁcacy of dual receptor blockade
with bosentan in reversing established endothelial and myogenic
dysfunction in later stages of diabetes. Bosentan not only improved
sensitivity to Ach as also seenwithmetformin but it also improvedmax-
imum relaxation which was different than complete lack of effect of
metformin treatment on this end point, which was intriguing. Given
that hyperglycemia is a potent stimulant for ET-1 synthesis, one would
predict that with glycemic control ET-1 levels would be normalized as
we have shown with early glycemic control (Sachidanandam et al.,
2009). In this study, we did not measure circulating and tissue ET-1
levels. The lack of effect of metformin on maximum relaxation may be
due to failure of suppressing ET-1 levels and needs to be conﬁrmed.
Bosentan also improved myogenic tone, which was quite pro-
nounced at higher end of the pressure-response curve. ET-1, being the
most potent vasoconstrictor, bosentan-mediated improvement of tone
may sound counterintuitive. Myogenic reactivity is the inherent ability
of vascular smoothmuscle to respond to changes in pressure the vessels
are exposed to and plays a critical role in certain vascular beds including
cerebral, coronary and renal circulation to regulate blood ﬂow. While
enhanced tone is detrimental, lack of tone development is also detri-
mental as the vessels lose their ability to regulate lumen diameter and
hence blood ﬂow. Myogenic reactivity in response to changes in pres-
sure the vessels are exposed to requires proper actin cytoskeleton ar-
rangement. We have shown that oxidative stress, peroxynitrite in
particular, nitrates ﬁlamentous F-actin and impairs myogenic tone
development (Kelly-Cobbs et al., 2012). ET-1, a potent pro-oxidant,
may be acting through this mechanism which needs to be further
267M. Abdelsaid et al. / Life Sciences 118 (2014) 263–267conﬁrmed by studying total nitrotyrosine formation and actin nitration
in bosentan-treated animals. It also has to be noted that the auto-
regulatory range for middle cerebral arteries is 80 to 120 mm Hg,
after which vessels show forced dilation. The ﬁnding that bosentan
improves tone even at higher end of this range in diabetic animals
suggests that bosentan provides protection at higher pressures.
Interestingly, blood pressure was increased in bosentan-treated an-
imals. We observed this effect in our previous studies which employed
younger rats and used both tail-cuff and telemetry approaches to mea-
sure blood pressure (A. Kelly-Cobbs et al., 2011; A.I. Kelly-Cobbs et al.,
2011; Li et al., 2011).While we do not have an explanation for this ﬁnd-
ing as bosentan has been reported to lower blood pressure in other
studies involving hypertensive animal models, blood pressure observed
is similar to what we have reported with selective ETB blockade
(A. Kelly-Cobbs et al., 2011; A.I. Kelly-Cobbs et al., 2011). It is also possi-
ble that the renal ET system is altered in diabetic rats contributing to el-
evated blood pressure with treatment. Nevertheless, the important
conclusion is that dual receptor blockade restores cerebrovascular func-
tion independent of changes in blood pressure in diabetes.
There are several limitations of the current study that need to be
recognized. First, we did not study mechanisms underlying cerebro-
vascular endothelial and myogenic function in diabetes and whether
treatment with metformin or bosentan affects different signaling path-
ways. Second, our goal was to determine whether established vascular
dysfunction in diabetes can be reversed and how this compares to
age-matched control animals. As such we did not include control ani-
mals treated with metformin or bosentan. Third, we did not study the
impact of glycemic control on local and circulating ET-1 levels and
cerebrovascular ET receptor distribution to determinewhether the pro-
tective effects of metformin are mediated via modulation of the ET
system. Nevertheless, numerous studies have shown that glycemic
control is an effective strategy in prevention and reduction of micro-
vascular complications of diabetes, however, the impact of glycemic
control on cerebrovascular complications remains unknown (Stettler
et al., 2006; Akalin et al., 2009). Finally, there is evidence that ETB recep-
tors may not be involved in mediating vasoconstriction of human pial
arteries (Pierre and Davenport, 1999). Whether this applies to entire
cerebral circulation or limited to vial vessels in humans is not known
but it is an important point to be considered in the evaluation of the
therapeutic potential of ET receptor antagonists. Taken together with
our previous studies, the ﬁndings of the current study suggest that
glycemic control offers preventive and some therapeutic potential for
cerebrovascular dysfunction in diabetes. Late ET receptor antagonism,
however, is more effective in improving endothelial and especially
myogenic function in the cerebrovasculature in experimental diabetes.
The impact of chronic regulation of cerebrovascular function by these
approaches on cerebrovascular complications including cognitive
impairment and stroke warrants future research.
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